USD 27.01
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ESALF | 0 | -3.5 | 5.3 | -20.5 | -35.2 | -41.9 | -48.2 | -64.4 | -37.0 | 33.8 |
| S&P 500 | -0.3 | 1.4 | 1.1 | 5.0 | 11.8 | 24.7 | 40.3 | 88.1 | 196.6 | 34448.4 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ESALF |
| name | Eisai Co., Ltd. |
| price | 27.01 |
| changes percentage | 0 |
| change | 0 |
| day low | 27.01 |
| day high | 28 |
| year high | 49.23 |
| year low | 24.86 |
| market cap | 7491610094 |
| price avg 50 | 28.7084 |
| price avg 200 | 36.71735 |
| exchange | PNK |
| volume | 100 |
| avg volume | 2148 |
| open | 28 |
| previous close | 27.01 |
| eps | 0.92 |
| pe | 29.36 |
| earnings announcement | 2025-02-07T03:30:00.000+0000 |
| shares outstanding | 277364313 |
| timestamp | 2025-01-24 00:00:00 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0000000000 | |||
| revenue | 741751000000 | 744402000000 | -0.36 |
| gross profit | 586418000000 | 543475000000 | 7.90 |
| gross profit ratio | 0.79 | 0.73 | 8.29 |
| research and development expenses | 169021000000 | 156691000000 | 7.87 |
| operating expenses | 533010000000 | 504255000000 | 5.70 |
| interest income | 10804000000 | 4623000000 | 133.70 |
| interest expense | 2388000000 | 2266000000 | 5.38 |
| ebitda | 103609000000 | 79201000000 | 30.82 |
| ebitdaratio | 0.14 | 0.11 | 31.29 |
| operating income | 53408000000 | 39220000000 | 36.18 |
| operating income ratio | 0.07 | 0.05 | 36.66 |
| net income | 42407000000 | 55432000000 | -23.50 |
| net income ratio | 0.06 | 0.07 | -23.22 |
| eps | 147.86 | 193.31 | -23.51 |
Revenue Growth: revenue decreased to 741,751 million in 2024 from 744,402 million in 2023 representing a change of -0.36%. This indicates a sales shrinking, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 533,010 million in 2024 from 504,255 million in 2023 representing a change of 5.7%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 103,609 million in 2024 from 79,201 million in 2023 representing a change of 30.82%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Net Income: Net income decreased to 42,407 million in 2024 from 55,432 million in 2023 representing a change of -23.5%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 147.86 in 2024 from 147.86 in 2023 representing a change of -23.51%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Gross Profit: Gross Profit increased to 586,418 million in 2024 from 543,475 million in 2023 representing a change of 7.9%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 169,021 million in 2024 from 156,691 million in 2023 representing a change of 7.87%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Income: Operating income increased to 53,408 million in 2024 from 39,220 million in 2023 representing a change of 36.18%. The increase in operating income indicates better operational performance and increased profitability.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0000000000 | |||
| revenue | 189029000000 | 190496000000 | -0.77 |
| gross profit | 149272000000 | 154390000000 | -3.31 |
| gross profit ratio | 0.79 | 0.81 | -2.56 |
| research and development expenses | 41736000000 | 44547000000 | -6.31 |
| operating expenses | 141280000000 | 147929000000 | -4.49 |
| interest income | 3277000000 | 3108000000 | 5.44 |
| interest expense | 715000000 | 845000000 | -15.38 |
| ebitda | 18054000000 | 16443000000 | 9.80 |
| ebitdaratio | 0.1 | 0.09 | 10.65 |
| operating income | 7992000000 | 6461000000 | 23.70 |
| operating income ratio | 0.04 | 0.03 | 24.66 |
| net income | 10581000000 | 13309000000 | -20.50 |
| net income ratio | 0.06 | 0.07 | -19.88 |
| eps | 36.95 | 46.36 | -20.30 |
Revenue Growth: revenue decreased to 189,029 million in 2025Q1 from 190,496 million in 2024Q4 representing a change of -0.77%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 149,272 million in 2025Q1 from 154,390 million in 2024Q4 representing a change of -3.31%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 41,736 million in 2025Q1 from 44,547 million in 2024Q4 representing a change of -6.31%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Net Income: Net income decreased to 10,581 million in 2025Q1 from 13,309 million in 2024Q4 representing a change of -20.5%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 36.95 in 2025Q1 from 36.95 in 2024Q4 representing a change of -20.3%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Operating Expenses: Operating Expenses decreased to 141,280 million in 2025Q1 from 147,929 million in 2024Q4 representing a change of -4.49%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 18,054 million in 2025Q1 from 16,443 million in 2024Q4 representing a change of 9.8%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 7,992 million in 2025Q1 from 6,461 million in 2024Q4 representing a change of 23.7%. The increase in operating income indicates better operational performance and increased profitability.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0000000000 | |||
| total assets | 1393799000000 | 1263350000000 | 10.33 |
| total liabilities | 494824000000 | 440779000000 | 12.26 |
| total equity | 898975000000 | 822571000000 | 9.29 |
| cash and cash equivalents | 304678000000 | 267350000000 | 13.96 |
| short term investments | 445000000 | 540000000 | -17.59 |
| long term investments | 58420000000 | 52818000000 | 10.61 |
| total current assets | 722983000000 | 621847000000 | 16.26 |
| total non current assets | 670816000000 | 641503000000 | 4.57 |
| total current liabilities | 304472000000 | 298945000000 | 1.85 |
| total non current liabilities | 190352000000 | 141834000000 | 34.21 |
| common stock | 44986000000 | 44986000000 | 0.00 |
| retained earnings | 526490000000 | 522774000000 | 0.71 |
| total debt | 159405000000 | 170918000000 | -6.74 |
Total Assets: Total Assets increased to 1,393,799 million in 2024 from 1,263,350 million in 2023 representing a change of 10.33%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 898,975 million in 2024 from 822,571 million in 2023 representing a change of 9.29%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 304,678 million in 2024 from 267,350 million in 2023 representing a change of 13.96%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 722,983 million in 2024 from 621,847 million in 2023 representing a change of 16.26%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to 526,490 million in 2024 from 522,774 million in 2023 representing a change of 0.71%. This indicates an accumulated profits.
Total Debt: Total Debt decreased to 159,405 million in 2024 from 170,918 million in 2023 representing a change of -6.74%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 494,824 million in 2024 from 440,779 million in 2023 representing a change of 12.26%. This indicates an increase in overall liabilities.
Short Term Investments: Short Term Investments decreased to 445 million in 2024 from 540 million in 2023 representing a change of -17.59%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 304,472 million in 2024 from 298,945 million in 2023 representing a change of 1.85%. This indicates a higher short-term debt burden.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0000000000 | |||
| total assets | 1420247000000 | 1393799000000 | 1.90 |
| total liabilities | 500551000000 | 494825000000 | 1.16 |
| total equity | 919696000000 | 898975000000 | 2.30 |
| cash and cash equivalents | 303935000000 | 304678000000 | -0.24 |
| short term investments | 0 | 445000000 | -100.00 |
| long term investments | 59620000000 | 58420000000 | 2.05 |
| total current assets | 733222000000 | 722237000000 | 1.52 |
| total non current assets | 687025000000 | 671562000000 | 2.30 |
| total current liabilities | 311018000000 | 304472000000 | 2.15 |
| total non current liabilities | 189533000000 | 190353000000 | -0.43 |
| common stock | 44986000000 | 44986000000 | 0.00 |
| retained earnings | 514225000000 | 526490000000 | -2.33 |
| total debt | 182334000000 | 206746000000 | -11.81 |
Total Assets: Total Assets increased to 1,420,247 million in 2025Q1 from 1,393,799 million in 2024Q4 representing a change of 1.9%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 919,696 million in 2025Q1 from 898,975 million in 2024Q4 representing a change of 2.3%. This indicates an increase in shareholders' equity.
Total Current Assets: Total Current Assets increased to 733,222 million in 2025Q1 from 722,237 million in 2024Q4 representing a change of 1.52%. This indicates a better liquidity position.
Total Debt: Total Debt decreased to 182,334 million in 2025Q1 from 206,746 million in 2024Q4 representing a change of -11.81%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 500,551 million in 2025Q1 from 494,825 million in 2024Q4 representing a change of 1.16%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 303,935 million in 2025Q1 from 304,678 million in 2024Q4 representing a change of -0.24%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 0 million in 2025Q1 from 445 million in 2024Q4 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 311,018 million in 2025Q1 from 304,472 million in 2024Q4 representing a change of 2.15%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to 514,225 million in 2025Q1 from 526,490 million in 2024Q4 representing a change of -2.33%. This indicates an accumulated losses.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0000000000 | |||
| net change in cash | 37328000000 | -42283000000 | 188.28 |
| operating cash flow | 55993000000 | -1772000000 | 3259.88 |
| free cash flow | 31170000000 | -36331000000 | 185.79 |
| capital expenditure | -24823000000 | -34559000000 | 28.17 |
| depreciation and amortization | 39398000000 | 39981000000 | -1.46 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 0 | 0 | NaN |
| accounts payables | 0 | -501000000 | 100.00 |
| inventory | 0 | -36885000000 | 100.00 |
| acquisitions net | 0 | 5611000000 | -100.00 |
| investments in property plant and equipment | -24823000000 | -34559000000 | 28.17 |
| net cash used for investing activites | -25321000000 | -22723000000 | -11.43 |
| debt repayment | 33256000000 | 31172000000 | 6.69 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | -45915000000 | -45893000000 | -0.05 |
| net cash used provided by financing activities | -22720000000 | -24522000000 | 7.35 |
| cash at end of period | 304678000000 | 267350000000 | 13.96 |
| accounts receivables | 0 | 37386000000 | -100.00 |
| cash at beginning of period | 267350000000 | 309633000000 | -13.66 |
Net Change in Cash: Net Change in Cash increased to 37,328 million in 2024 from -42,283 million in 2023 representing a change of 188.28%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 55,993 million in 2024 from -1,772 million in 2023 representing a change of 3259.88%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 31,170 million in 2024 from -36,331 million in 2023 representing a change of 185.79%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2024 from 501 million in 2023 representing a change of 100.0%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to 0 million in 2024 from 37,386 million in 2023 representing a change of -100.0%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Capital Expenditure: Capital Expenditure increased to -24,823 million in 2024 from -34,559 million in 2023 representing a change of 28.17%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Dividends Paid: Dividends Paid decreased to -45,915 million in 2024 from -45,893 million in 2023 representing a change of -0.05%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0000000000 | |||
| operating cash flow | -8581000000 | 18059000000 | -147.52 |
| free cash flow | -13195000000 | 23265000000 | -156.72 |
| capital expenditure | -4614000000 | 5206000000 | -188.63 |
| depreciation and amortization | 10062000000 | 9982000000 | 0.80 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 0 | 0 | NaN |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | 0 | 0 | NaN |
| inventory | 0 | 0 | NaN |
| acquisitions net | 9489000000 | 1600000000 | 493.06 |
| investments in property plant and equipment | -4614000000 | 5206000000 | -188.63 |
| net cash used for investing activites | 3584000000 | -2982000000 | 220.19 |
| debt repayment | 0 | -6870000000 | 100.00 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | -8479000000 | 0 | NaN |
| dividends paid | -22963000000 | 0 | NaN |
| net cash used provided by financing activities | -11890000000 | -9344000000 | -27.25 |
| net change in cash | -743000000 | 19887000000 | -103.74 |
| cash at end of period | 303935000000 | 304678000000 | -0.24 |
| cash at beginning of period | 304678000000 | 284791000000 | 6.98 |
Net Change in Cash: Net Change in Cash decreased to -743 million in 2025Q1 from 19,887 million in 2024Q4 representing a change of -103.74%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -8,581 million in 2025Q1 from 18,059 million in 2024Q4 representing a change of -147.52%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -13,195 million in 2025Q1 from 23,265 million in 2024Q4 representing a change of -156.72%. This indicates a decrease in cash generated after accounting for capital expenditures.
Dividends Paid: Dividends Paid decreased to -22,963 million in 2025Q1 from 0 million in 2024Q4 representing a change of nan%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
Capital Expenditure: Capital Expenditure decreased to -4,614 million in 2025Q1 from 5,206 million in 2024Q4 representing a change of -188.63%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q2 2025 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2024-03-31 | 2023-03-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 2586.27 | 2595.93 | -0.37 |
| net income per share | 147.86 | 193.31 | -23.51 |
| operating cash flow per share | 195.23 | -6.18 | 3259.37 |
| free cash flow per share | 108.68 | -126.7 | 185.78 |
| cash per share | 1063.88 | 934.21 | 13.88 |
| book value per share | 3134.47 | 2868.53 | 9.27 |
| tangible book value per share | 2012.24 | 1829.16 | 10.01 |
| shareholders equity per share | 3053.02 | 2789.68 | 9.44 |
| interest debt per share | 564.13 | 447.66 | 26.02 |
| market cap | 1743475437000 | 2151824528000 | -18.98 |
| enterprise value | 1598202437000 | 2010579528000 | -20.51 |
| pe ratio | 41.11 | 38.82 | 5.91 |
| price to sales ratio | 2.35 | 2.89 | -18.69 |
| pocfratio | 31.14 | -1214.35 | 102.56 |
| pfcf ratio | 55.93 | -59.23 | 194.44 |
| pb ratio | 1.99 | 2.69 | -25.98 |
| ptb ratio | 1.99 | 2.69 | -25.98 |
| ev to sales | 2.15 | 2.7 | -20.23 |
| enterprise value over ebitda | 15.5 | 23.04 | -32.73 |
| ev to operating cash flow | 28.54 | -1134.64 | 102.52 |
| ev to free cash flow | 51.27 | -55.34 | 192.65 |
| earnings yield | 0.02 | 0.03 | -5.58 |
| free cash flow yield | 0.02 | -0.02 | 205.89 |
| debt to equity | 0.18 | 0.16 | 15.48 |
| debt to assets | 0.11 | 0.1 | 14.58 |
| net debt to ebitda | -1.41 | -1.62 | 12.96 |
| current ratio | 2.37 | 2.08 | 14.09 |
| interest coverage | 22.37 | 17.67 | 26.57 |
| income quality | 0.91 | -0.04 | 2400.64 |
| dividend yield | 0.03 | 0.02 | 23.48 |
| payout ratio | 1.08 | 0.83 | 30.78 |
| sales general and administrative to revenue | 0.5 | 0.48 | 4.88 |
| research and ddevelopement to revenue | 0.23 | 0.23 | -1.95 |
| intangibles to total assets | 0.23 | 0.24 | -2.12 |
| capex to operating cash flow | 0.44 | -19.5 | 102.27 |
| capex to revenue | 0.03 | 0.05 | -27.92 |
| capex to depreciation | 0.63 | 0.86 | -27.11 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 3187.0 | 3483.3 | -8.51 |
| roic | 0.03 | 0.05 | -33.04 |
| return on tangible assets | 0.04 | 0.06 | -31.11 |
| graham net net | 211.05 | 131.68 | 60.27 |
| working capital | 418511000000 | 323257000000 | 29.47 |
| tangible asset value | 577116000000 | 524524000000 | 10.03 |
| net current asset value | 228159000000 | 181423000000 | 25.76 |
| invested capital | 905264000000 | 787937000000 | 14.89 |
| average receivables | 202232000000 | 197603000000 | 2.34 |
| average payables | 55392000000 | 97445500000 | -43.16 |
| average inventory | 157534000000 | 119712500000 | 31.59 |
| days sales outstanding | 106.88 | 91.82 | 16.41 |
| days payables outstanding | 56.3 | 178.21 | -68.41 |
| days of inventory on hand | 410.39 | 288.2 | 42.40 |
| receivables turnover | 3.41 | 3.98 | -14.10 |
| payables turnover | 6.48 | 2.05 | 216.55 |
| inventory turnover | 0.89 | 1.27 | -29.78 |
| roe | 0.05 | 0.07 | -30.11 |
| capex per share | 86.55 | 120.52 | -28.18 |
ROE: Return on Equity (ROE) decreased to 0.05 on 2024-03-31 from 0.07 on 2023-03-31, representing a change of -30.11%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 41.11 on 2024-03-31 from 38.82 on 2023-03-31, representing a change of 5.91%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 2.37 on 2024-03-31 from 2.08 on 2023-03-31, representing a change of 14.09%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.18 on 2024-03-31 from 0.16 on 2023-03-31, representing a change of 15.48%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-06-30 Q1 | 2024-03-31 Q4 | Q/Q change % | |
|---|---|---|---|
| ESALF | |||
| calendar year | 2024 | 2023 | NaN |
| revenue per share | 660.14 | 663.67 | -0.53 |
| net income per share | 36.95 | 46.37 | -20.31 |
| operating cash flow per share | -29.97 | 62.92 | -147.63 |
| free cash flow per share | -42.52 | 81.05 | -152.46 |
| cash per share | 1061.42 | 1063.01 | -0.15 |
| book value per share | 3211.82 | 3131.93 | 2.55 |
| tangible book value per share | 2044.4 | 2010.6 | 1.68 |
| shareholders equity per share | 3128.25 | 3050.54 | 2.55 |
| interest debt per share | 639.25 | 723.22 | -11.61 |
| market cap | 1912800725520 | 1744889096292 | 9.62 |
| enterprise value | 1791199725520 | 1646957096292 | 8.76 |
| pe ratio | 45.19 | 32.78 | 37.89 |
| price to sales ratio | 10.12 | 9.16 | 10.47 |
| pocfratio | -222.91 | 96.62 | -330.71 |
| pfcf ratio | -157.1 | 75.0 | -309.46 |
| pb ratio | 2.14 | 1.99 | 7.16 |
| ptb ratio | 2.14 | 1.99 | 7.16 |
| ev to sales | 9.48 | 8.65 | 9.60 |
| enterprise value over ebitda | 66.97 | 56.87 | 17.76 |
| ev to operating cash flow | -208.74 | 91.2 | -328.89 |
| ev to free cash flow | -147.11 | 70.79 | -307.81 |
| earnings yield | 0.01 | 0.01 | -27.48 |
| free cash flow yield | -0.01 | 0.01 | -147.74 |
| debt to equity | 0.2 | 0.24 | -13.79 |
| debt to assets | 0.13 | 0.15 | -13.45 |
| net debt to ebitda | -4.55 | -3.38 | -34.45 |
| current ratio | 2.36 | 2.37 | -0.62 |
| interest coverage | 18.75 | 7.65 | 145.25 |
| income quality | -0.81 | 1.36 | -159.77 |
| dividend yield | 0.01 | 0 | NaN |
| payout ratio | 2.17 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0.54 | -100.00 |
| research and ddevelopement to revenue | 0.22 | 0.23 | -5.58 |
| intangibles to total assets | 0.24 | 0.23 | 1.93 |
| capex to operating cash flow | -0.42 | 0.29 | -245.33 |
| capex to revenue | 0.02 | 0.03 | -30.41 |
| capex to depreciation | 0.36 | 0.52 | -31.49 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 1612.72 | 1783.96 | -9.60 |
| roic | 0.01 | 0.0 | 102.90 |
| return on tangible assets | 0.01 | 0.01 | -21.52 |
| graham net net | 184.04 | 210.88 | -12.72 |
| working capital | 422204000000 | 417765000000 | 1.06 |
| tangible asset value | 585408000000 | 577115000000 | 1.44 |
| net current asset value | 232671000000 | 227412000000 | 2.31 |
| invested capital | 921844000000 | 904518000000 | 1.92 |
| average receivables | 211281500000 | 201695000000 | 4.75 |
| average payables | 50878000000 | 40010500000 | 27.16 |
| average inventory | 182626000000 | 168948500000 | 8.10 |
| days sales outstanding | 97.77 | 102.62 | -4.72 |
| days payables outstanding | 176.12 | 59.72 | 194.91 |
| days of inventory on hand | 431.47 | 435.35 | -0.89 |
| receivables turnover | 0.92 | 0.88 | 4.96 |
| payables turnover | 0.51 | 1.51 | -66.09 |
| inventory turnover | 0.21 | 0.21 | 0.90 |
| roe | 0.01 | 0.02 | -22.29 |
| capex per share | 12.55 | 18.14 | -30.78 |
ROE: Return on Equity (ROE) decreased to 0.01 on 2024-06-30 Q1 from 0.02 on 2024-03-31 Q4, representing a change of -22.29%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 45.19 on 2024-06-30 Q1 from 32.78 on 2024-03-31 Q4, representing a change of 37.89%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.20 on 2024-06-30 Q1 from 0.24 on 2024-03-31 Q4, representing a change of -13.79%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Current Ratio: Current Ratio decreased to 2.36 on 2024-06-30 Q1 from 2.37 on 2024-03-31 Q4, representing a change of -0.62%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Positive Sentiment: Discounted Cash Flow value is 27.2 which is higher than current price 27.01, indicates the company may be undervalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2025-01-24 07:01:50
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve overall survival in patients with a type of esophageal cancer in a late-stage trial, the companies said on Friday.
Sentiment: Positive
Publish Date: 2025-01-24 06:45:00
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial.
Sentiment: Positive
Publish Date: 2024-11-14 13:29:00
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab as a treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (Early Alzheimer's disease) who are apolipoprotein E ε4 (ApoE ε4)* non-carriers or heterozygotes with confirmed amyloid pathology.1 Eisai had requested a re-examination of the prior negative opinion adopted by the CHMP in July 2024. In accordance with European Medicines Agency regulatory process, the European Commission is expected to make a final decision on the marketing authorization application (MAA) of lecanemab based on the CHMP recommendation within 67 days of receipt of CHMP opinion.2
Sentiment: Positive
Publish Date: 2024-11-14 11:23:00
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab as a treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (Early Alzheimer's disease) who are apolipoprotein E ε4 (ApoE ε4)* non-carriers or heterozygotes with confirmed amyloid pathology.1 Eisai had requested a re-examination of the prior negative opinion adopted by the CHMP in July 2024. In accordance with European Medicines Agency regulatory process, the European Commission is expected to make a final decision on the marketing authorization application (MAA) of lecanemab based on the CHMP recommendation within 67 days of receipt of CHMP opinion.2
Sentiment: Positive
Publish Date: 2024-11-14 11:17:28
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment.
Sentiment: Positive
Publish Date: 2024-11-11 10:38:10
Leqembi has just started its commercial journey, and in order to achieve an appropriate or even discounted multiple, relatively modest penetration of the drug in the US would be needed. Lenvima is also continuing with solid growth, seeming to be on path to hit the forecast targets in 2025. The EMA decision to turn down Leqembi for now was disappointing, but it's already been approved in Japan, US, China and the UK.
Sentiment: Positive
Publish Date: 2024-11-09 06:46:01
Eisai Co., Ltd. (OTCPK:ESALF) Q2 2025 Earnings Conference Call November 8, 2024 1:00 AM ET Company Participants Haruo Naito - Representative Corporate Officer and CEO Akiko Nakahama - VP-Chief Portfolio Officer Japan / Asia Filing and Registration Katsuya Haruna - Group Officer & Executive Vice President, U.S. Business Operations Kazuhiko Tamura - Vice President, Eisai Demand Chain Systems Tomo Ogawa - Department Manager, Clinical Operations Conference Call Participants Hidemaru Yamaguchi - Citigroup Seiji Wakao - JPMorgan Kazuaki Hashiguchi - Daiwa Securities Kasumi Haruta - UBS Securities Operator Thank you very much for taking your time out of your busy schedule to attend the earnings announcement session by Eisai Company Limited.
Sentiment: Neutral
Publish Date: 2024-11-07 23:19:00
STOCKHOLM , Nov. 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from April 2024 through March 2025. Eisai now expects Leqembi sales to total JPY 42.5 billion (approximately SEK 3 billion) for the period, down from JPY 56.5 billion announced in May.
Sentiment: Positive
Publish Date: 2024-10-31 19:43:00
STOCKHOLM , Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. Leqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD).
Sentiment: Positive
Publish Date: 2024-10-30 19:30:00
-New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and caregiver perspectives on five-year treatment with lecanemab -- Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD-
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
